The SOUL trial showed that oral semaglutide was safe in patients with type 2 diabetes and atherosclerotic cardiovascular ...

Semaglutide improved maximum walking distance in patients with type 2 diabetes and symptomatic peripheral artery disease.

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be presented at ECO 2025 - covering burden, and the value of treatment and prevention ...

Semaglutide has been tested in several ... cardiovascular disease, heart failure, chronic kidney disease, liver disease and other related cardiometabolic diseases. It has a cumulative exposure ...

A recent clinical trial reveals that Wegovy, a popular weight-loss drug containing semaglutide, shows promising results in ...

A global trial finds Wegovy and Ozempic significantly improve liver health in patients and treats those with advanced fatty ...

In a major clinical trial, the weight loss drug Wegovy has been able to treat a serious form of liver disease in the majority ...

Beyond its weight loss and diabetes control, semaglutide is increasingly being studied for its potential role in treating a range of chronic illnesses, from heart disease to kidney failure.

A decision is expected in the fourth quarter of 2025.